BTG put its foot to the floor
Drug developer BTG's (BTG) latest acquisition is expected to contribute to profits doubling by 2017, helping to overcome any qualms about a lofty valuation.The £2.8 billion cap bought US technology company PneumRx for £147 million...
23 December 2014
